Cyclobenzaprine Use in Atrial Fibrillation Management

Introduction to Cyclobenzaprine in AF

The American College of Cardiology and other guideline societies suggest that cyclobenzaprine can be used safely in patients with atrial fibrillation, as it does not directly affect cardiac rhythm or ventricular rate control, with a strength of evidence based on multiple studies 1, 2, 3, 4.

Cyclobenzaprine, a centrally-acting muscle relaxant, does not interfere with standard rate control agents used in AF, including beta-blockers, calcium channel blockers, digoxin, or amiodarone, according to the American Heart Association 1, 2, 3.
The American College of Cardiology recommends that if a patient with AF experiences increased heart rate after starting cyclobenzaprine, the existing rate control regimen should be optimized rather than discontinuing the muscle relaxant, based on evidence from clinical practice 1, 4.

The European Society of Cardiology notes that cyclobenzaprine has mild anticholinergic properties that theoretically could cause tachycardia, though this is rarely clinically significant in the context of AF where rate control medications are already prescribed, with a low level of evidence 2, 3.
Patients with AF should have their ventricular rate controlled to 60-80 bpm at rest and 90-115 bpm during moderate exercise before adding any medication that might theoretically increase heart rate, as recommended by the American Heart Association 2, 3.

The American College of Cardiology suggests confirming resting heart rate is 60-80 bpm and exercise heart rate is 90-115 bpm with current medications before initiating cyclobenzaprine, based on clinical guidelines 1, 2, 3.
Avoid cyclobenzaprine in acute myocardial infarction, heart failure with acute decompensation, or significant arrhythmias other than controlled AF, as recommended by the European Society of Cardiology 1, 4.
Use caution in elderly patients due to anticholinergic effects, but AF itself is not a contraindication, according to the American Geriatrics Society 2, 3.
Start cyclobenzaprine at standard doses of 5 mg three times daily, as there is no need for dose adjustment based solely on AF diagnosis, based on evidence from pharmacological studies 1, 2.
Recheck heart rate at rest and with activity within 1-2 weeks of starting cyclobenzaprine, and if ventricular rate increases above target range, uptitrate existing rate control medications rather than discontinuing cyclobenzaprine, as recommended by the American College of Cardiology 1, 2, 3, 4.

Do not confuse cyclobenzaprine with antiarrhythmic drugs, as it has no direct electrophysiologic effects on atrial tissue or AV nodal conduction, according to the American Heart Association 1, 3.
Do not withhold necessary muscle relaxant therapy solely due to AF diagnosis, as the presence of AF does not contraindicate cyclobenzaprine use when rate control is adequate, based on clinical evidence 2, 4.
Cyclobenzaprine does not affect stroke risk or anticoagulation requirements in AF patients, according to the European Society of Cardiology 1, 3, 4.